Global Pharmaceutical Company Licenses Ajinomoto's Corynex™ Recombinant Protein Expression System Following Successful Proof-of-Concept

Published: Mar 05, 2013

RALEIGH, N.C.--(BUSINESS WIRE)--Ajinomoto North America, Inc. today announced a top-tier, global pharmaceutical company has licensed its CorynexTM Recombinant Protein Expression System. The pharma assessed the Technology with a number of recombinant proteins. Based upon a successful proof-of-concept, the company has entered a full licensing agreement that allows for the in-house use of Ajinomoto’s proprietary CorynexTM Expression. CorynexTM uses the gram-positive Corynebacterium glutamicum to reduce purification steps, lower costs, and increase yield. CorynexTM does not require cell lysis or protein refolding, eliminating the need for endotoxin removal steps. The system also speeds production through a fast-growing bacterial model, shorter fermentation run to produce proteins and cheaper bacterium medium cost.

Back to news